ash cll highlights: ibrutinib-venetoclax combination & undetectable mrd in ighv-mutated patients
Published 1 year ago • 519 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
1:00
ash 2022 lba: results from final analysis of alpine - zanubrutinib vs ibrutinib for r/r cll/sll
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
5:00
venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline cll: updates from gaia/cll13
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
2:09
ash highlights in cll: moving towards fixed-duration treatment, the role of mrd & alpine results
-
2:18
first-line ibrutinib and venetoclax in cll
-
1:53
cll highlights from ash 2023: the flair study
-
6:43
key highlights in cll: clinical trial updates & the role of combination therapies and novel btkis
-
6:09
what were the cll highlights at ash 2020?
-
1:54
glow: assessing ibrutinib plus venetoclax in cll
-
1:38
front-line use of ibrutinib for cll in a real-world setting
-
1:56
emerging ibrutinib-based combinations in cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
2:15
highlights in cll at ash and future research
-
1:36
obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in cll
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll